Vincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Vincerx Pharma (NASDAQ:VINCFree Report) in a report published on Monday, Benzinga reports.

Vincerx Pharma Trading Up 15.6 %

VINC stock opened at $5.85 on Monday. The firm’s 50-day moving average is $3.76 and its two-hundred day moving average is $1.92. Vincerx Pharma has a 52 week low of $0.61 and a 52 week high of $9.37. The company has a market capitalization of $125.07 million, a price-to-earnings ratio of -2.53 and a beta of 1.09.

Institutional Trading of Vincerx Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC raised its holdings in shares of Vincerx Pharma by 16.9% in the 4th quarter. Citadel Advisors LLC now owns 197,359 shares of the company’s stock worth $233,000 after purchasing an additional 28,530 shares in the last quarter. Sage Rhino Capital LLC raised its holdings in shares of Vincerx Pharma by 1.0% in the 3rd quarter. Sage Rhino Capital LLC now owns 1,703,413 shares of the company’s stock worth $1,720,000 after purchasing an additional 16,476 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Vincerx Pharma in the 2nd quarter worth approximately $176,000. ExodusPoint Capital Management LP raised its holdings in shares of Vincerx Pharma by 8.9% in the 2nd quarter. ExodusPoint Capital Management LP now owns 426,472 shares of the company’s stock worth $554,000 after purchasing an additional 34,724 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Vincerx Pharma in the 1st quarter worth approximately $28,000. 44.02% of the stock is currently owned by institutional investors.

Vincerx Pharma Company Profile

(Get Free Report)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.

Featured Stories

Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.